Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Methantheline (compound)


PubChem
Name: methantheline
PubChem Compound ID: 4097
Molecular formula: C21H26NO3+
Molecular weight: 340.436 g/mol
Synonyms:
Ammonium, diethyl (2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate; MTB 51; nchembio747-comp13; Metaxan; Methantheline bromide; .beta.-Diethylaminoethyl 9-xanthenecarboxylate methobromide; Banthine; Methanthelinium; Methelina; SPBio_002966.
show more »
DrugBank
Identification
Name: methantheline
Name (isomeric): DB00940
Drug Type: small molecule
Synonyms:
Banthine Bromide; Methanthelinium; MTB 51; Methantheline Bromide; Methanthelinum; Methanthelinium Bromide; Methanthine Bromide
Brand: Vagamin, Resobantin, Methanide, Gastron, Avagal, Dixamone Bromide, Methelina, Doladene, Mantheline, Vagantin, Ulcine, Xanteline, Banthine, Gastrin I, Frenogastrico, Gastrin-1 Human, Metaxan, Metantyl, Banthin, Asabaine, Gastrosedan, Ulcudexter
Category: Anticholinergic Agents, Antispasmodics
CAS number: 5818-17-7
Pharmacology
Indication: For the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children.
Pharmacology:
Methantheline is a synthetic quarternary ammonium antimuscarinic used to relieve cramps or spasms of the stomach, intestines, and bladder. It can be used together with antacids or other medicines, such as H2-receptor antagonists, in the treatment of peptic ulcer. Methantheline inhibits muscarinic actions at postganglionic parasympathetic neuroeffec...
show more »
Mechanism of Action:
Methantheline inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and...
show more »
Absorption: Rapidly absorbed.
Biotransformation: Hepatic, by enzymatic hydrolysis.
Toxicity: Symptoms of overdose: blurred vision (continuing) or changes in near vision, clumsiness or unsteadiness, confusion, convulsions, difficulty in breathing, muscle weakness (severe), or tiredness (severe), dizziness, drowsiness (severe), dryness of mouth, nose, or throat (severe), fast heartbeat, fever, hallucinations, slurred speech, unusual excitement, nervousness, restlessness, or irritability, unusual warmth, dryness, and flushing of skin.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
TriprolidineTriprolidine and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
TacrineThe therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Methantheline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
HaloperidolThe anticholinergic increases the risk of psychosis and tardive dyskinesia
TrospiumTrospium and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
TrimethobenzamideTrimethobenzamide and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.

Targets